Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.